Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s Lymphoma

Hainsworth, John D.; Litchy, Sharlene; Burris, Howard A.; Scullin, Daniel C.; Corso, Steven; Yardley, Denise A.; Morrissey, Lisa H.; Greco, F. Anthony

doi:10.1200/jco.2002.08.674

Cited by 420 publications

(260 citation statements)

References 14 publications

Supporting

Mentioning

247

Contrasting

Unclassified

Order By: Relevance

“…Rituximab alone was also studied in patients with a more aggressive presentation, needing treatment at diagnosis or after some follow-up without treatment (Hainsworth et al, 2002). The RR, just after four infusions, was comparable with the one observed in relapsing patients (50% and less than 10% of CR).…”

Section: Rituximab In Flmentioning

confidence: 92%

Rituximab therapy in malignant lymphoma

2007

View full text Add to dashboard Cite

Section: Rituximab In Flmentioning

confidence: 92%

Rituximab therapy in malignant lymphoma

2007

View full text Add to dashboard Cite

“…This combines antibodies that specifically target antigens selectively expressed on tumour cells and cytotoxic effector mechanisms. Successful clinical use includes the treatment of breast cancer by HER-2-specific trastuzumab (Goldenberg, 1999), follicular non-Hodgkin B-cell lymphoma by CD20 specific rituximab (Hainsworth, 2000).…”

mentioning

confidence: 99%

EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges

Chaudry

Sales

Rosenberger³

et al. 2007

Br J Cancer

View full text Add to dashboard Cite

Despite advances in surgery and adjuvant regimes, gastrointestinal malignancy remains a major cause of neoplastic mortality. Immunotherapy is an emerging and now successful treatment modality for numerous cancers that relies on the manipulation of the immune system and its effector functions to eradicate tumour cells. The discovery that the pan-epithelial homotypic cell adhesion molecule EpCAM is differentially expressed on gastrointestinal tumours has made this a viable target for immunotherapy. Clinical trials using naked anti EpCAM antibody, immunoconjugates, anti-idiotypic and dendritic cell vaccines have met variable success. The murine IgG2a Edrecolomab was shown to reduce mortality and morbidity at a level slightly lower than treatment with 5FU and Levamisole when administered to patients with advanced colorectal carcinoma in a large randomised controlled trial. Fully human and trifunctional antibodies that specifically recruit CD3-positive lymphocytes are now being tested clinically in the treatment of minimal residual disease and ascites. Although clinical trials are in their infancy, the future may bring forth an EpCAM mediated approach for the effective activation and harnessing of the immune system to destroy a pathological aberrance that has otherwise largely escaped its attention.

show abstract

“…Current studies have shown that a prolonged exposure to rituximab after the end of the primary treatment may reduce relapse rate and improve event-free survival in patients with FL and MCL [13][14][15]. In follicular lymphoma, rituximab maintenance therapy is now part of the standard of care in relapsed disease [10,15].…”

Section: Discussionmentioning

confidence: 99%

“…Hochster et al [12] reported a significant prolongation of response duration and even survival by R maintenance in patients with previously untreated advanced-stage FL responding to initial therapy without R comprising chemotherapy by cyclophosphamide, vincristine, and prednisone (CVP) alone. In former investigations, Hainsworth et al [13] and Ghielmini et al [14] already had found that R maintenance was beneficial when given to patients with FL who achieved a partial remission or complete remission after initial singleagent first-line R therapy. In a recent publication, R maintenance after R chemotherapy was investigated in patients with recurring or refractory FL and MCL.…”

Section: Introductionmentioning

confidence: 99%